or anti-I, and is rarely severe. We present an unusual case of a 21-year-old morbidly obese woman with severe, acute CHD due to the rare anti-Pr, who was transferred to our institution from an outside hospital with severe symptomatic anemia. Significant labs were as follows: hemoglobin 4.1 g/dL, retic 18.9%, haptoglobin <8 mg/dL, lactate dehydrogenase 312 U/L, and ferritin 1,115.6 ng/mL (~3x upper limit of reference range). A strong cold autoantibody was identified, and a specimen was sent to a reference lab for further workup. In the meantime, two units of packed red blood cells (PRBC) were ordered for urgent transfusion. One unit of O negative PRBC that was crossmatch compatible using prewarmed plasma was issued on waiver. At the reference lab, a strong cold autoantibody with anti-Pr specificity was confirmed, and underlying alloantibodies were excluded. The warm-washed cells were used to perform the DAT, which showed polyspecific and C3 4+ positivity (IgG was negative). Four additional units of type A positive PRBC that were crossmatch compatible using prewarmed plasma were transfused during her hospitalization (all units were given via blood warmer). The patient was also treated with oral prednisone. Extensive autoimmune and infectious disease (including Monospot and Mycoplasma IgM) workups were negative. The cold agglutinin titer was positive at 1:1,024. The patient was discharged on hospital day six with a hemoglobin stable 8.7 g/dL.
Introduction: Platelet refractoriness is a common problem leading to delays in treatment, increased length of hospital stay, and higher inpatient costs. A 39-year-old woman with a past medical history of insulin-dependent diabetes and hypothyroidism presented with malaise, non-healing mouth ulcer, gum bleeding, hematochezia, and left axillary abscess. She was diagnosed with precursor B-cell acute lymphocytic leukemia. Due to severe thrombocytopenia and need for chemotherapy optimization, the patient received multiple platelet transfusions during her hospitalization. She became refractory, ABO-compatible platelets were transfused without success, and human leukocyte antigen (HLA) antibody testing revealed 65 antibodies. HLA antigen typing was attempted, but the patient's white blood cell count was too low to obtain results, and buccal testing was not available at the institution. Neurosurgery planned for an Ommaya reservoir placement for intrathecal chemotherapy' however, the procedure was delayed due to severe thrombocytopenia (2,000/uL).
Methods:
We contacted the patient's biological sisters and coordinated efforts to have specimens drawn and sent to our institution for HLA typing. The patient's mother had samples drawn on site for genotyping. The patient's father was estranged. Results from genotyping the patient's mother and two sisters allowed us to determine the patient's most probable HLA genotype. Conclusion: We worked closely with our blood centers to obtain HLA-matched platelets with a combination of compatible and least incompatible haplotypes. Neurosurgery required a platelet count of 50,000/uL to perform the procedure. Following the second apheresis unit, the platelet count improved to 54,000/uL with a corrected count increment of 15,600. This case presented a refractory thrombocytopenic patient with antibodies to nearly all HLA antigens, who required an invasive life-saving procedure, and whom we were unable to HLA genotype. Resourcefulness and teamwork facilitated the successful resolution of this challenging clinical problem allowing the patient to have a shorter hospital stay and improved clinical outcome.
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Formation of a Cold Reactive Anti-A1 After Transfusion With A1 Red Blood Cell Units in the Setting of Gross Hemolysis
Jeffrey Petersen, Darshana Jhala, MD; Corporal Michael J. Crescenz VA Medical Center and University of Pennsylvania, Philadelphia
Introduction: Anti-A1 antibodies can be found as a naturally occurring cold IgM antibody in A subgroup patients, but without clinical significance. The presence of anti-A1 in the overwhelming majority of cases should not affect transfusion management or preclude the use of A1 red blood cells (RBCs). It is known that clinically significant warm-reactive anti-A1 that reacts at 37°C can be clinically significant. In a previous case report, the antibody formed only after alloimmunization with donor A1 RBCs. Here, we report a rare case of a cold-reactive anti-A1 antibody that formed as an alloantibody (after multiple transfusions with group A1 RBC units) in a 76-year-old male patient (A subgroup) with history of myelodysplastic syndrome and metastatic carcinoma who presented with hemolytic anemia. Prior to presentation, the patient had previously typed as blood type A without any reverse typing reaction for anti-A; as a result, the patient had been transfused with group A1 RBCs over the course of two weeks. Just four days prior to his admission, the patient had a febrile transfusion reaction associated with his A1 RBC transfusion; at that time, the patient left with a hemoglobin of 8.7 g/dL. Methods: Given his presenting hemoglobin of 6.1 g/dL, transfusion medicine laboratory related testing (ABO
